<DOC>
	<DOCNO>NCT00083083</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , fludeoxyglucose F18 positron emission tomography ( ^18FDG-PET ) , may improve ability detect disease progression help doctor predict patient 's response treatment plan effective treatment . PURPOSE : This phase II trial study well ^18FDG-PET image work detect disease progression determine response treatment patient undergo chemoradiotherapy locally advance non-small cell lung cancer .</brief_summary>
	<brief_title>Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before After Treatment Locally Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether peak standardize uptake value ( SUV ) fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) shortly definitive chemoradiotherapy predictive long-term survival patient inoperable stage IIB III non-small cell lung cancer . Secondary - Determine whether max SUV FDG-PET shortly definitive chemoradiotherapy predictive long-term survival patient . - Determine whether post-treatment image use peak max SUV FDG-PET shortly definitive chemoradiotherapy predictive local disease control patient . - Determine whether pre-treatment image use technique predictive long-term survival local disease control patient . - Correlate , possible , Ki-67 expression overall survival patient assess image technique . OUTLINE : This diagnostic , multicenter study . Before start chemoradiotherapy , patient undergo baseline whole-body positron emission tomography ( PET ) imaging . Patients receive fludeoxyglucose F 18 ( ^18FDG ) IV follow 50-70 minute later PET image . Patients receive concurrent definitive radiotherapy chemotherapy . Patients enrol treatment-oriented clinical trial receive therapy per trial . Other patient receive standard thoracic radiotherapy ( dose ≥ 60 Gy ) standard chemotherapy comprise platin ( cisplatin carboplatin ) second non-platin , non-gemcitabine drug ( etoposide , vinblastine , vinorelbine , paclitaxel , docetaxel ) . Approximately 14 week completion chemoradiotherapy adjuvant chemotherapy ( give ) , patient undergo post-treatment ^18FDG-PET imaging . Patients follow every 3 month 2 year every 6 month least 1 year . PROJECTED ACCRUAL : A total 250 patient ( include least 75 stage IIB/IIIA disease least 75 stage IIIB disease ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Clinical stage IIB III disease No small cell carcinoma No stage IV disease* No diffuse bronchoalveolar subtype No plan definitive surgical resection NOTE : *Patients evidence stage IV disease positron emission tomography eligible evidence confirm mean AND physician still plan proceed definitive chemoradiation Planning treatment definitive chemoradiotherapy May treat another Radiation Therapy Oncology Group protocol ( except phase I study ) OR conventional concurrent NSCLC chemoradiotherapy Radiotherapy ≥ 60 Gy AND chemotherapy include concurrent platinumbased therapy No brain metastasis head CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Medically suitable early concurrent chemoradiotherapy ( radiotherapy dose ≥ 60 Gy ) Able tolerate positron emission tomography image No poorly control diabetes ( define fast glucose level &gt; 200 mg/dL ) No malignancy within past 3 year except basal cell squamous cell skin cancer carcinoma situ Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy No anticipated use adjuvant biologic therapy beyond 14 week completion radiotherapy Chemotherapy See Disease Characteristics No anticipated use adjuvant chemotherapy beyond 14 week completion radiotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior thoracic radiotherapy No concurrent intensitymodulated radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>